Radiotherapy Induced Immunogenic Cell Death by Remodeling Tumor Immune Microenvironment

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Dec 19

PMID 36532071

Authors

Songxin Zhu

Yuming Wang

Jun Tang

Min Cao

Affiliations

Soon will be listed here.

Abstract

Emerging evidence indicates that the induction of radiotherapy(RT) on the immunogenic cell death (ICD) is not only dependent on its direct cytotoxic effect, changes in the tumor immune microenvironment also play an important role in it. Tumor immune microenvironment (TIME) refers to the immune microenvironment that tumor cells exist, including tumor cells, inflammatory cells, immune cells, various signaling molecules and extracellular matrix. TIME has a barrier effect on the anti-tumor function of immune cells, which can inhibit all stages of anti-tumor immune response. The remodeling of TIME caused by RT may affect the degree of immunogenicity, and make it change from immunosuppressive phenotype to immunostimulatory phenotype. It is of great significance to reveal the causes of immune escape of tumor cells, especially for the treatment of drug-resistant tumor. In this review, we focus on the effect of RT on the TIME, the mechanism of RT in reversing the TIME to suppress intrinsic immunity, and the sensitization effect of the remodeling of TIME caused by RT on the effectiveness of immunotherapy.

Citing Articles

Beyond Tumor Borders: Intratumoral Microbiome Effects on Tumor Behavior and Therapeutic Responses.

Harmak Z, Kone A, Ghouzlani A, Ghazi B, Badou A Immune Netw. 2025; 24(6):e40.

PMID: 39801738 PMC: 11711125. DOI: 10.4110/in.2024.24.e40.

Nanotechnology-Based Strategies for Safe and Effective Immunotherapy.

Hong S, Park J, Oh Y, Cho H, Kim K Molecules. 2025; 29(24.

PMID: 39769944 PMC: 11676242. DOI: 10.3390/molecules29245855.

Tumor cell membrane-based vaccines: A potential boost for cancer immunotherapy.

Yang M, Zhou J, Lu L, Deng D, Huang J, Tang Z Exploration (Beijing). 2024; 4(6):20230171.

PMID: 39713208 PMC: 11655317. DOI: 10.1002/EXP.20230171.

Immunogenic cell death-related cancer-associated fibroblast clusters and prognostic risk model in cervical cancer.

Wu F, Xu Y APL Bioeng. 2024; 8(4):046114.

PMID: 39691350 PMC: 11650426. DOI: 10.1063/5.0240772.

Immunogenic cell death: A new strategy to enhancing cancer immunotherapy.

Dou L, Fang Y, Yang H, Ai G, Shen N Hum Vaccin Immunother. 2024; 20(1):2437918.

PMID: 39655738 PMC: 11639453. DOI: 10.1080/21645515.2024.2437918.

References

Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y . TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554(7693):544-548. PMC: 6028240. DOI: 10.1038/nature25501. View

Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M . Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood. 2007; 109(9):3812-9. DOI: 10.1182/blood-2006-07-035972. View

Patel R, Hernandez R, Carlson P, Grudzinski J, Bates A, Jagodinsky J . Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade. Sci Transl Med. 2021; 13(602). PMC: 8449934. DOI: 10.1126/scitranslmed.abb3631. View

Derer A, Frey B, Fietkau R, Gaipl U . Immune-modulating properties of ionizing radiation: rationale for the treatment of cancer by combination radiotherapy and immune checkpoint inhibitors. Cancer Immunol Immunother. 2015; 65(7):779-86. PMC: 11028616. DOI: 10.1007/s00262-015-1771-8. View

Golden E, Pellicciotta I, Demaria S, Barcellos-Hoff M, Formenti S . The convergence of radiation and immunogenic cell death signaling pathways. Front Oncol. 2012; 2:88. PMC: 3413017. DOI: 10.3389/fonc.2012.00088. View

Mastelic-Gavillet B, Balint K, Boudousquie C, Gannon P, Kandalaft L . Personalized Dendritic Cell Vaccines-Recent Breakthroughs and Encouraging Clinical Results. Front Immunol. 2019; 10:766. PMC: 6470191. DOI: 10.3389/fimmu.2019.00766. View

Mehdizadeh S, Bayatipoor H, Pashangzadeh S, Jafarpour R, Shojaei Z, Motallebnezhad M . Immune checkpoints and cancer development: Therapeutic implications and future directions. Pathol Res Pract. 2021; 223:153485. DOI: 10.1016/j.prp.2021.153485. View

Meziani L, Deutsch E, Mondini M . Macrophages in radiation injury: a new therapeutic target. Oncoimmunology. 2018; 7(10):e1494488. PMC: 6169587. DOI: 10.1080/2162402X.2018.1494488. View

Antonia S, Villegas A, Daniel D, Vicente D, Murakami S, Hui R . Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(20):1919-1929. DOI: 10.1056/NEJMoa1709937. View

10.

Shevtsov M, Sato H, Multhoff G, Shibata A . Novel Approaches to Improve the Efficacy of Immuno-Radiotherapy. Front Oncol. 2019; 9:156. PMC: 6433964. DOI: 10.3389/fonc.2019.00156. View

11.

Obeid M, Tesniere A, Ghiringhelli F, Fimia G, Apetoh L, Perfettini J . Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2006; 13(1):54-61. DOI: 10.1038/nm1523. View

12.

Topalian S, Drake C, Pardoll D . Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015; 27(4):450-61. PMC: 4400238. DOI: 10.1016/j.ccell.2015.03.001. View

13.

Zhang J, Saenz-Lopez Larrocha P, Zhang B, Wainwright D, Dhar P, Wu J . Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC tumors respond to PD1/PD-L1 blockade therapy. J Immunother Cancer. 2019; 7(1):223. PMC: 6709558. DOI: 10.1186/s40425-019-0693-y. View

14.

Molla M, Gironella M, Miquel R, Tovar V, Engel P, Biete A . Relative roles of ICAM-1 and VCAM-1 in the pathogenesis of experimental radiation-induced intestinal inflammation. Int J Radiat Oncol Biol Phys. 2003; 57(1):264-73. DOI: 10.1016/s0360-3016(03)00523-6. View

15.

Zeng J, See A, Phallen J, Jackson C, Belcaid Z, Ruzevick J . Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys. 2013; 86(2):343-9. PMC: 3963403. DOI: 10.1016/j.ijrobp.2012.12.025. View

16.

Schaue D, McBride W . Opportunities and challenges of radiotherapy for treating cancer. Nat Rev Clin Oncol. 2015; 12(9):527-40. PMC: 8396062. DOI: 10.1038/nrclinonc.2015.120. View

17.

Walker L, Sansom D . The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol. 2011; 11(12):852-63. DOI: 10.1038/nri3108. View

18.

Qin X, Yang C, Xu H, Zhang R, Zhang D, Tu J . Cell-Derived Biogenetic Gold Nanoparticles for Sensitizing Radiotherapy and Boosting Immune Response against Cancer. Small. 2021; 17(50):e2103984. DOI: 10.1002/smll.202103984. View

19.

Lauret Marie Joseph E, Kirilovsky A, Lecoester B, El Sissy C, Boullerot L, Rangan L . Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy. J Immunother Cancer. 2021; 9(7). PMC: 8261891. DOI: 10.1136/jitc-2020-002256. View

20.

Yan J, Wang G, Xie L, Tian H, Li J, Li B . Engineering Radiosensitizer-Based Metal-Phenolic Networks Potentiate STING Pathway Activation for Advanced Radiotherapy. Adv Mater. 2021; 34(10):e2105783. DOI: 10.1002/adma.202105783. View